| Non-oncogene addiction to SIRT3 plays a critical role in lymphomagenesis M Li, YL Chiang, CA Lyssiotis, MR Teater, JY Hong, H Shen, L Wang, ... Cancer cell 35 (6), 916-931. e9, 2019 | 97 | 2019 |
| Updates on the epigenetic roles of sirtuins T Kosciuk, M Wang, JY Hong, H Lin Current opinion in chemical biology 51, 18-29, 2019 | 62 | 2019 |
| Pharmacological and genetic perturbation establish SIRT5 as a promising target in breast cancer YLN Abril, IR Fernandez, JY Hong, YL Chiang, DA Kutateladze, Q Zhao, ... Oncogene 40 (9), 1644-1658, 2021 | 55 | 2021 |
| A small‐molecule SIRT2 inhibitor that promotes K‐Ras4a lysine fatty‐acylation NA Spiegelman, JY Hong, J Hu, H Jing, M Wang, IR Price, J Cao, M Yang, ... ChemMedChem 14 (7), 744-748, 2019 | 52 | 2019 |
| Direct Comparison of SIRT2 Inhibitors: Potency, Specificity, Activity‐Dependent Inhibition, and On‐Target Anticancer Activities NA Spiegelman, IR Price, H Jing, M Wang, M Yang, J Cao, JY Hong, ... ChemMedChem 13 (18), 1890-1894, 2018 | 52 | 2018 |
| Novel lysine-based thioureas as mechanism-based inhibitors of sirtuin 2 (SIRT2) with anticancer activity in a colorectal cancer murine model AS Farooqi, JY Hong, J Cao, X Lu, IR Price, Q Zhao, T Kosciuk, M Yang, ... Journal of medicinal chemistry 62 (8), 4131-4141, 2019 | 49 | 2019 |
| Simultaneous inhibition of SIRT2 deacetylase and defatty-acylase activities via a PROTAC strategy JY Hong, H Jing, IR Price, J Cao, JJ Bai, H Lin ACS Medicinal Chemistry Letters 11 (11), 2305-2311, 2020 | 42 | 2020 |
| Histone H2B deacylation selectivity: exploring chromatin’s dark matter with an engineered sortase ZA Wang, SD Whedon, M Wu, S Wang, EA Brown, A Anmangandla, ... Journal of the American Chemical Society 144 (8), 3360-3364, 2022 | 31 | 2022 |
| A glycoconjugated SIRT2 inhibitor with aqueous solubility allows structure-based design of SIRT2 inhibitors JY Hong, IR Price, JJ Bai, H Lin ACS chemical biology 14 (8), 1802-1810, 2019 | 30 | 2019 |
| Sirtuin modulators in cellular and animal models of human diseases JY Hong, H Lin Frontiers in Pharmacology 12, 735044, 2021 | 25 | 2021 |
| Pharmacological advantage of SIRT2-selective versus pan-SIRT1–3 inhibitors JY Hong, I Fernandez, A Anmangandla, X Lu, JJ Bai, H Lin ACS Chemical Biology 16 (7), 1266-1275, 2021 | 20 | 2021 |
| Reversible lysine fatty acylation of an anchoring protein mediates adipocyte adrenergic signaling RA Bagchi, EL Robinson, T Hu, J Cao, JY Hong, CA Tharp, H Qasim, ... Proceedings of the National Academy of Sciences 119 (7), e2119678119, 2022 | 16 | 2022 |
| Emerging roles of Sirtuin 2 in cardiovascular diseases A Taneja, V Ravi, JY Hong, H Lin, NR Sundaresan The FASEB Journal 35 (10), e21841, 2021 | 16 | 2021 |
| Translational activation of ATF4 through mitochondrial anaplerotic metabolic pathways is required for DLBCL growth and survival M Li, MR Teater, JY Hong, NR Park, C Duy, H Shen, L Wang, Z Chen, ... Blood cancer discovery 3 (1), 50-65, 2022 | 15 | 2022 |
| Development of a NanoBRET assay to validate inhibitors of Sirt2-mediated lysine deacetylation and defatty-acylation that block prostate cancer cell migration A Vogelmann, M Schiedel, N Wössner, A Merz, D Herp, S Hammelmann, ... RSC Chemical Biology 3 (4), 468-485, 2022 | 13 | 2022 |
| Simultaneous inhibition of Sirtuin 3 and cholesterol homeostasis targets acute myeloid leukemia stem cells by perturbing fatty acid β-oxidation and inducing lipotoxicity C O’Brien, T Ling, JM Berman, R Culp-Hill, JA Reisz, V Rondeau, ... Haematologica 108 (9), 2343, 2023 | 12 | 2023 |
| High-throughput enzyme assay for screening inhibitors of the ZDHHC3/7/20 acyltransferases JY Hong, MIP Malgapo, Y Liu, M Yang, C Zhu, X Zhang, P Tolbert, ... ACS chemical biology 16 (8), 1318-1324, 2021 | 11 | 2021 |
| Substrate-dependent modulation of Sirt2 by a fluorescent probe, 1-aminoanthracene D Bi, J Yang, JY Hong, P Parikh, N Hinds, J Infanti, H Lin, BP Weiser Biochemistry 59 (40), 3869-3878, 2020 | 9 | 2020 |
| HPLC-based enzyme assays for sirtuins JY Hong, X Zhang, H Lin ADP-ribosylation and NAD+ Utilizing Enzymes: Methods and Protocols, 225-234, 2018 | 7 | 2018 |
| SIRT3 is a novel metabolic driver of and therapeutic target for chemotherapy resistant Dlbcls M Li, YL Chiang, C Lyssiotis, M Teater, H Shen, L Wang, JY Hong, H Jin, ... Blood 130, 643, 2017 | 4 | 2017 |
